TY - JOUR
T1 - Evolution and immunopathology of chikungunya virus informs therapeutic development
AU - Henderson Sousa, Filipa
AU - Ghaisani Komarudin, Amalina
AU - Findlay-Greene, Fern
AU - Bowolaksono, Anom
AU - Sasmono, R. Tedjo
AU - Stevens, Craig
AU - Barlow, Peter G.
N1 - Funding Information:
The authors acknowledge the funding of the Medical Research Council (MR/ S019790), RISTEKDIKTI and the Newton Fund.
Publisher Copyright:
© 2023. Published by The Company of Biologists Ltd.
PY - 2023/4
Y1 - 2023/4
N2 - Chikungunya virus (CHIKV), a mosquito-borne alphavirus, is an emerging global threat identified in more than 60 countries across continents. The risk of CHIKV transmission is rising due to increased global interactions, year-round presence of mosquito vectors, and the ability of CHIKV to produce high host viral loads and undergo mutation. Although CHIKV disease is rarely fatal, it can progress to a chronic stage, during which patients experience severe debilitating arthritis that can last from several weeks to months or years. At present, there are no licensed vaccines or antiviral drugs for CHIKV disease, and treatment is primarily symptomatic. This Review provides an overview of CHIKV pathogenesis and explores the available therapeutic options and the most recent advances in novel therapeutic strategies against CHIKV infections.
AB - Chikungunya virus (CHIKV), a mosquito-borne alphavirus, is an emerging global threat identified in more than 60 countries across continents. The risk of CHIKV transmission is rising due to increased global interactions, year-round presence of mosquito vectors, and the ability of CHIKV to produce high host viral loads and undergo mutation. Although CHIKV disease is rarely fatal, it can progress to a chronic stage, during which patients experience severe debilitating arthritis that can last from several weeks to months or years. At present, there are no licensed vaccines or antiviral drugs for CHIKV disease, and treatment is primarily symptomatic. This Review provides an overview of CHIKV pathogenesis and explores the available therapeutic options and the most recent advances in novel therapeutic strategies against CHIKV infections.
KW - Antiviral compounds
KW - Chikungunya pathogenesis
KW - Chikungunya virus
KW - Immunomodulatory drugs
KW - Monoclonal antibodies
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85151794398&partnerID=8YFLogxK
U2 - 10.1242/dmm.049804
DO - 10.1242/dmm.049804
M3 - Review article
C2 - 37014125
AN - SCOPUS:85151794398
SN - 1754-8403
VL - 16
JO - DMM Disease Models and Mechanisms
JF - DMM Disease Models and Mechanisms
IS - 4
M1 - dmm049804
ER -
